Clinical Development and Regulatory Approval Risk: MIRA's success hinges on its drug candidates successfully navigating clinical trials and securing regulatory approvals; failure at any stage could significantly delay or prevent commercialization.

Funding and Capital Needs Risk: Developing pharmaceutical products is capital-intensive, and MIRA may require substantial additional financing, which it may not be able to obtain on favorable terms or at all, to complete its development programs and commercialize products.

Intellectual Property Protection Risk: MIRA's ability to protect its drug candidates and technology through patents and other intellectual property rights is critical; failure to secure or defend these rights could expose it to competition and diminish its value.